Literature DB >> 11952298

Epidermolysis bullosa acquisita: treatment with intravenous immunoglobulins.

K Gourgiotou1, D Exadaktylou, K Aroni, E Rallis, E Nicolaidou, H Paraskevakou, A D Katsambas.   

Abstract

Epidermolysis bullosa acquisita (EBA) is a rare autoimmune bullous disorder that is often difficult to treat. Few cases have been reported and therapy consists mainly of combinations of systemic steroids, immunosuppressants and, recently, administration of intravenous human immunoglobulin (IVIg). We describe a case of EBA in which our therapeutic choices were limited due to the patient's poor general condition, including extensive infection of the lesions and a history of pulmonary tuberculosis. The patient was treated with IVIg at a dose of 400 mg/kg per day for 5 consecutive days every 4 weeks. The treatment was well tolerated and the results were satisfactory. It seems that IVIg, due to its possible immunomodulatory mode of action, can be an efficacious therapeutic agent in this rare autoimmune disease.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11952298     DOI: 10.1046/j.1468-3083.2002.00386.x

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN: 0926-9959            Impact factor:   6.166


  8 in total

Review 1.  Epidermolysis bullosa acquisita.

Authors:  Rishu Gupta; David T Woodley; Mei Chen
Journal:  Clin Dermatol       Date:  2012 Jan-Feb       Impact factor: 3.541

Review 2.  Epidermolysis bullosa acquisita: autoimmunity to anchoring fibril collagen.

Authors:  Mei Chen; Gene H Kim; Lori Prakash; David T Woodley
Journal:  Autoimmunity       Date:  2011-09-28       Impact factor: 2.815

Review 3.  High-dose intravenous immunoglobulin (IVIG) therapy in autoimmune skin blistering diseases.

Authors:  Norito Ishii; Takashi Hashimoto; Detlef Zillikens; Ralf J Ludwig
Journal:  Clin Rev Allergy Immunol       Date:  2010-04       Impact factor: 8.667

4.  Epidermolysis bullosa acquisita with moderately severe Dysphagia due to esophageal strictures.

Authors:  Jenny Tu; Prasad W Kumarasinghe
Journal:  Indian J Dermatol       Date:  2011-03       Impact factor: 1.494

Review 5.  Epidermolysis bullosa acquisita: current diagnosis and therapy.

Authors:  Christine R Mehren; Robert Gniadecki
Journal:  Dermatol Reports       Date:  2011-11-28

6.  Shifting Focus in the Therapeutics of Immunobullous Disease.

Authors:  Abhishek De; Asad Ansari; Nidhi Sharma; Aarti Sarda
Journal:  Indian J Dermatol       Date:  2017 May-Jun       Impact factor: 1.494

Review 7.  Intravenous Immunoglobulins: Mode of Action and Indications in Autoimmune and Inflammatory Dermatoses.

Authors:  Lyubomir A Dourmishev; Dimitrina V Guleva; Ljubka G Miteva
Journal:  Int J Inflam       Date:  2016-01-18

Review 8.  Epidermolysis Bullosa Acquisita: The 2019 Update.

Authors:  Hiroshi Koga; Catherine Prost-Squarcioni; Hiroaki Iwata; Marcel F Jonkman; Ralf J Ludwig; Katja Bieber
Journal:  Front Med (Lausanne)       Date:  2019-01-10
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.